Geron (GERN) Income from Continuing Operations (2010 - 2026)
Geron's (GERN) quarterly Income from Continuing Operations came in at 3568000.0 in Q1 2026, up 81.94% year-on-year from 1961129.12 in Q1 2025, and up 87.61% quarter-over-quarter from 28792000.0 in Q4 2025.
Geron (GERN) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Geron has disclosed Income from Continuing Operations across 17 years of filings, most recently posting 3568000.0 for Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 3568000.0, up 81.94% year-over-year; the trailing twelve-month figure through Mar 2026 was 66941000.0 (up 51.16% YoY), and the FY2025 annual result was 83125000.0, up 51.85% from the prior year.
- Income from Continuing Operations came in at 3568000.0 for Q1 2026 at Geron, up from 28792000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3568000.0 in Q1 2026 to a low of 67320000.0 in Q2 2024.
- The 5-year median for Income from Continuing Operations is 30042000.0 (2022), against an average of 34489941.18.
- Across the five-year window, Income from Continuing Operations tumbled 68.39% in 2023 and jumped 81.94% in 2026, its largest moves.
- Geron's Income from Continuing Operations stood at 42721000.0 in 2022, then retreated by 21.75% to 52014000.0 in 2023, then jumped by 54.63% to 23597000.0 in 2024, then declined by 22.02% to 28792000.0 in 2025, then jumped by 87.61% to 3568000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3568000.0 (Q1 2026), 28792000.0 (Q4 2025), and 18267000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Geron | 753,046.88 | 753,046.88 | - | -3.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.57 Mn |
| Dec 31, 2025 | -28.79 Mn |
| Sep 30, 2025 | -18.27 Mn |
| Jun 30, 2025 | -16.31 Mn |
| Mar 31, 2025 | -19.75 Mn |
| Dec 31, 2024 | -23.60 Mn |
| Sep 30, 2024 | -26.38 Mn |
| Jun 30, 2024 | -67.32 Mn |
| Mar 31, 2024 | -55.33 Mn |
| Dec 31, 2023 | -52.01 Mn |
| Sep 30, 2023 | -44.71 Mn |
| Jun 30, 2023 | -49.22 Mn |
| Mar 31, 2023 | -38.16 Mn |
| Dec 31, 2022 | -42.72 Mn |
| Sep 30, 2022 | -40.91 Mn |
| Jun 30, 2022 | -29.23 Mn |
| Mar 31, 2022 | -30.04 Mn |
| Dec 31, 2021 | -32.01 Mn |
| Sep 30, 2021 | -26.62 Mn |
| Jun 30, 2021 | -29.56 Mn |